A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute (Maximus)

Inclusion Criteria:

• The patient must be >= 18 years of age;
• Symptomatic ischemic heart disease (CCS class 1 -4 , Braunwald class IB, IC, IIB, IIC, IIIB,IIIC) and/or objective evidence of myocardial ischemia;
• Vessel size of >= 2.5 and <= 3.5mm.
• Target lesions which can be covered by stent in a manner lesion stent ratio of at least 1.5.
• Acceptable candidate for coronary artery bypass surgery (CABG);
• Target lesion stenosis is >50% and <100% (TIMI flow I) (visual estimate);
• The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB).

Exclusion Criteria:

• Women of childbearing potential;
• Impaired renal function (creatinine > 2.0 mg/dl or 177 µmol/l);
• Any patient who has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis);
• Recipient of heart transplant;
• Restenotic or lesion in graft.
• Patient with a life expectancy less than 12 months;
• Known allergies to aspirin, clopidogrel bisulphate (Plavix), ticlopidine (Ticlid), heparin or stainless steel;
• Any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study;
• Currently participating in an investigational drug or another device study, or subject to inclusion in another investigational drug or another device study during follow-up.

Angiographic Exclusion criteria:

• Unprotected left main coronary artery disease with >=50% stenosis;
• Angiographic evidence of thrombus (thrombus larger than half the diameter of the vessel and/or requiring other interventions such as angiojet, exciser, thrombolysis, etc.);
• Ejection fraction <= 30%;